Compare Multi Hanna Kreasindo Tbk. (MHKI) vs Organon Pharma Indonesia Tbk. (SCPI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Multi Hanna Kreasindo Tbk. vs Organon Pharma Indonesia Tbk. — how do they compare? Multi Hanna Kreasindo Tbk. trades at Rp132 (market cap 517.5B, 6.46M 24h volume), while Organon Pharma Indonesia Tbk. trades at Rp29,000 (market cap 104.4B). The key difference: Multi Hanna Kreasindo Tbk. is far larger — about 5× Organon Pharma Indonesia Tbk.'s market cap. Which is the better fit depends on your goals.
| MHKI | SCPI | |
|---|---|---|
Market Cap | 517.5B | 104.4B |
Volume | 6.46M | — |
Lot | 64.61K | — |
Turnover | 855.43M | — |
Average Price | 132.41 | — |
Value | 855.43M | — |
Indicative Equilibrium Price | 132 | — |
Indicative Equilibrium Volume | 357 | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Multi Hanna Kreasindo Tbk.
PT Multi Hanna Kreasindo Tbk (Company), was established on September 23, 2004 based on Deed of Notary Drajat Dramaji, S.H., No.165. The company became effective commercially on September 23, 2004. The parent entity of the Company is PT Multi Hanna Sinergitama and the ultimate beneficial owners of the Company are Mr. Shahabuddin and Mr. Alwi.
Read more on MHKI →About Organon Pharma Indonesia Tbk.
PT Merck Sharp Dohme Pharma Tbk was established within the frame work of the Foreign Capital Investment Law No. 1 year 1967 as amended by Law No. 11 year 1970 based on Notarial Deed No. 17 dated 7 March 1972 of Djojo Muljadi, S.H. The company originally incorporated as PT. Essex Indonesia, as a joint venture between Schering Corporation, a worldwide, research-based pharmaceutical enterprise headquartered in the United States, and an Indonesian businessman.
Read more on SCPI →
